Deutsche Bank Maintains Buy on Medicis Pharmaceutical (MRX)

Deutsche Bank is out with its report today on Medicis Pharmaceutical MRX, maintaining Buy. In a note to clients, Deutsche Bank writes, "The outlook for Medicis's flagship Solodyn franchise has improved significantly over the past six months – based on a strong switch thus far to the new protected doses and considerable strengthening of the patent position. We continue to see Medicis capable of generating long-term mid-teens EPS growth, driven by its acne and aesthetics brands and its emerging development pipeline." Deutsche Bank maintains a $35 PT on MRX. At the time of posting, shares of MRX were trading at $28.05, up 0.18% from Friday's close.